CASI
CASI Pharmaceuticals Inc
$
2.330
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.380
Open
2.310
VWAP
2.32
Vol
26.10K
Mkt Cap
36.10M
Low
2.300
Amount
60.52K
EV/EBITDA(TTM)
--
Total Shares
13.40M
EV
47.61M
EV/OCF(TTM)
--
P/S(TTM)
1.19
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q2
FY2025Q1
0.00
-100%
--
--
6.28M
+57.7%
--
--
6.10M
+78.94%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for CASI Pharmaceuticals, Inc. (CASI) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 25.27%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+25.27%
In Past 3 Month
1 Analyst Rating
-35.62% Downside
Wall Street analysts forecast CASI stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CASI is 1.50 USD with a low forecast of 1.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold
-35.62% Downside
Current: 2.330
Low
1.50
Averages
1.50
High
1.50
-35.62% Downside
Current: 2.330
Low
1.50
Averages
1.50
High
1.50
HC Wainwright & Co.
Sean Lee
Strong Buy
Maintains
$6 → $4
2025-04-09
Reason
HC Wainwright & Co.
Sean Lee
Price Target
$6 → $4
2025-04-09
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for CASI Pharmaceuticals Inc (CASI.O) is -1.24, compared to its 5-year average forward P/E of -3.90. For a more detailed relative valuation and DCF analysis to assess CASI Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.90
Current PE
-1.24
Overvalued PE
0.11
Undervalued PE
-7.91
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-2.03
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.55
Undervalued EV/EBITDA
-5.61
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
3.69
Current PS
5.72
Overvalued PS
7.76
Undervalued PS
-0.38
Financials
Annual
Quarterly
FY2025Q2
YoY :
+4.93%
4.18M
Total Revenue
FY2025Q2
YoY :
+12.10%
-10.71M
Operating Profit
FY2025Q2
YoY :
+60.82%
-11.20M
Net Income after Tax
FY2025Q2
YoY :
+65.38%
-0.86
EPS - Diluted
FY2022Q4
YoY :
-66.79%
-4.27M
Free Cash Flow
FY2025Q2
YoY :
-5.12%
49.29
Gross Profit Margin - %
FY2025Q2
N/A
FCF Margin - %
FY2025Q2
YoY :
+83.02%
-320.36
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
957.9K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
104.0K
Volume
Months
6-9
0
0.0
Volume
Months
0-12
1
717.9K
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CASI News & Events
Events Timeline
2025-09-02 (ET)
2025-09-02
09:06:03
Casi Pharmaceuticals names Barbara Krebs-Pohl to its board of directors
2025-08-04 (ET)
2025-08-04
09:11:59
Casi Pharmaceuticals announces FDA clearance of CID-103 IND application
2025-07-21 (ET)
2025-07-21
16:12:50
Casi Pharmaceuticals CEO Wei-Wu He to step down, David Cory to succeed
Sign Up For More Events
Sign Up For More Events
News
8.5
08-18BenzingaDayforce Shares Surge Approximately 21%; Check Out 20 Stocks Making Moves in Premarket Trading
2.0
08-18NASDAQ.COMPremarket Stock Movements: PPCB, BTAI, TNXP, DAY, TPIC, and Other Notable Gainers and Losers
9.5
08-12NASDAQ.COMXenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates
Sign Up For More News
People Also Watch
VHC
VirnetX Holding Corp
14.930
USD
+6.64%
RAYA
Erayak Power Solution Group Inc
0.045
USD
-9.92%
INKT
Mink Therapeutics Inc
14.075
USD
+1.55%
KORE
KORE Group Holdings Inc
2.310
USD
-5.71%
SHOT
Safety Shot Inc
0.412
USD
-8.04%
ORIS
Oriental Rise Holdings Ltd
0.117
USD
-6.40%
HSON
Hudson Global Inc
9.870
USD
+3.68%
IXHL
Incannex Healthcare Inc
0.624
USD
-2.19%
FAQ
What is CASI Pharmaceuticals Inc (CASI) stock price today?
The current price of CASI is 2.33 USD — it has increased 1.3 % in the last trading day.
What is CASI Pharmaceuticals Inc (CASI)'s business?
What is the price predicton of CASI Stock?
What is CASI Pharmaceuticals Inc (CASI)'s revenue for the last quarter?
What is CASI Pharmaceuticals Inc (CASI)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for CASI Pharmaceuticals Inc (CASI)'s fundamentals?
How many employees does CASI Pharmaceuticals Inc (CASI). have?